More than 2100 delegates have already decided
to join us at the Congress!
REGISTRATION FEES
(VAT 19% included)
Full Registration
€ 150,00
Young Registration (≤35 years)
€ 100,00
More than 2100 delegates have already decided
to join us at the Congress!
REGISTRATION FEES
(VAT 19% included)
Full Registration
€ 150,00
Young Registration (≤35 years)
€ 100,00
Dear Colleagues,
The next IFCC webinar on “Alzheimer’s disease therapeutics & biofluid tests: Current practice and future prospects” will be held on Oct 28, 2021.
This session will provide an overview of the rapidly evolving landscape of: (i) the use, reporting and interpretation of cerebrospinal fluid (CSF) Alzheimer’s disease biomarkers in clinical care, (ii) the development of peripheral (i.e.,blood-based) biomarkers and assays for Alzheimer’s disease, and (iii) the state of disease-modifying therapeutics for Alzheimer’s disease, including current and future uses of biomarkers related to therapeutics.
Routine imaging technologies (e.g., magnetic resonance imaging) and observation of clinical syndromes have demonstrated only modest accuracy for diagnosing Alzheimer’s disease in cognitively impaired individuals. As such, biomarkers are needed to help differentiate neurodegenerative disorders with overlapping phenotypes, particularly in the early stages of disease when diagnosis can be challenging and there is the greatest treatment potential.
On the basis of extensive evidence, a core set of CSF biomarkers for Alzheimer’s disease are now recommended by the international community for use in patient care, and the ever-expanding data on blood-based biomarkers suggests new roles in research and patient care. For CSF biomarkers, we will review the clinical use scenarios and implementation considerations for clinical laboratories. For blood-based biomarkers, we will review key biomarkers and associated analytical approaches, as laboratorians need to be aware the strengths and weaknesses of these emerging assays and proposed use scenarios.
We will also review advancements indisease-modifying therapies for Alzheimer’s disease and discuss current applications of CSF and blood-based biomarker testing in clinical trials, and anticipated future uses in guiding therapy decisions.
Chair: Dr. Robert Rissman (USA)
A Certificate of participation will be provided at the end of this webinar. Please feel free to share this event in your social media with #IFCCLive Webinars
Register here:
https://www.workcast.com/register?cpak=5390610616631173
Time Zones: Live presentations starting at 9:30 AM Pacific Time (Vancouver), 6:30 PM European Time (Rome), 1:30 PM Argentina Time (Buenos Aires) on Oct 28, 2021
Please ensure that you carefully determine the time that the presentation will start in your global time zone. To convert to your time zone click here
If you miss the live event, on demand webinar will be available after 24 /48 hours of the live event.
Certificate of Participation: available for all participants.
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
Dear Colleagues,
The next IFCC webinar on “Common laboratory measures of dysglycaemia; Their strengths and weaknesses” will be held on Oct 27, 2021.
Diabetes Mellitus, and its precursor clinical syndromes, continue to grow in prevalence in developed and developing countries across the world. Clinical laboratory plays a crucial role in the diagnosis and management of diabetes to prevent short-term and long-term complications. Measurement of glucose, insulin, and HbA1c play vital roles in understanding and managing diabetes and over several decades laboratory professionals have improved their individual strengths, but also identified some significant weaknesses. No laboratory test is perfect, but it is vital that laboratory professionals are aware of any weaknesses and try to mitigate that risk so that the guidance that the laboratory provides to the clinician, and ultimately the patient, can be clear and balanced.
This seminar will allow the participant to identify the weaknesses with the measurement and reporting of glucose, insulin, and HbA1c, but also to recognize the laboratory techniques to minimize the risks associated with these weaknesses.
The webinar will contain three presentations of 20 min per speaker plus 20 min panel discussion.
Talk 1: Laboratory measurement of glucose
Speaker: Greg Ward
Department Head Biochemistry
Sullivan Nicolaides Pathology, Brisbane, Queensland, AU
Talk 2: Insulin analysis in hyperglycemia
Speaker: Paul Williams
Principal Research Fellow
The University of Sydney (Central Clinical School), NSW, AU
Talk 3: HbA1c – still the gold standard?
Speaker: Ken Sikaris
Director of Chemical Pathology
Melbourne Pathology, Melbourne, Victoria, AU
Chairperson: Dr. Tina Yen,
Chemical Pathologist
St George Hospital, Kogarah, NSW, au
Register here:
https://www.workcast.com/register?cpak=4552903128838838
Time Zones: Live presentations starting at 6:00 PM (Sydney - AEDT), 9:00 AM (Milan - CEST), 3:00 AM (US EDT) on Oct 27, 2021
Please ensure that you carefully determine the time that the presentation will start in your global time zone. To convert to your time zone click - https://www.timeanddate.com/worldclock/converter.html?iso=20211027T070000&p1=240&p2=105&p3=137&p4=179&p5=33&p6=248&p7=176&p8=157&p9=136&p10=19&p11=51&p12=111
If you miss the live event, on demand webinar will be available after 24 hours of the live event.
Certificate of Participation: available for all participants. Please
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
]]>
Dear Colleagues,
The next IFCC webinar: "Ethical dilemmas in laboratory medicine during a pandemic" will be held on 20 October
With its Task Force on Ethics, the IFCC creates a collective voice for ethical issues in Laboratory Medicine and raises awareness of ethics-related issues. The COVID 19 pandemic tests are our professional responsibility and demand that we do not simply perform tests and use technology uncritically.
In this webinar, we will first talk about the causes of the profoundly reduced life expectancy of Australia’s remote-dwelling Aborigines and describe demands upon the medical practitioner that are so fundamental that they are rarely encountered in "urban" medicine.
Then we will concentrate on how the Covid-19 pandemic is changing the research and society, focusing on the use of remnant clinical samples for research, often exempted from informed consent and the idea of collaboration with scientific research as a moral duty.
Finally, as this pandemic has emphasized many long-standing inequities in communities we will highlight the impact of long-standing medical conditions, challenges of testing and contact tracing, mistrust of medical institutions and vaccines.
Is this the time to propose a paradigm shift in health care and research ethics?
The Webinar will consist of three talks (20 minutes each) and will be followed by a panel discussion. Registrants will be able to ask questions to the presenters.
Chair: Dr. Nilda Fink
Please feel free to share this event on your social media with #IFCCLive Webinars
A certificate of participation will be provided at the end of this webinar.
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
IFCC eNews: October 2021 |
 |
| Full PDF version |
IN THIS ISSUE:
29th September 2021 IFCC webinar
"Quality management of medical test results during the pandemic"
IFCC has been involved in the fight against the COVID-19 pandemic since it began. This has included producing webinars for the training and education of laboratory professionals. Laboratory specialists from around the world are involved in the fight against the COVID-19 pandemic. Some of the main challenges remaining include the limited testing capacity for SARS-CoV-2, the professional training of specialists, and maintaining quality control during diagnosis, standardization, prognostication, and therapeutic monitoring of patients with COVID-19.
During the webinar, the speakers discussed:
- "Increasing the testing capacity for SARS-CoV-2 molecular detection by specimen pooling: a practical guide for diagnostic centers" – Dr. Daniel Cruceriu
- "Specialist role in the analytical phase of laboratory diagnosis of SARS-CoV-2” – Dr. Mirela Ahmadi
- "Quality Management - EQC a useful tool for IQC" – Dr. Constanta Popa and Dr. Georgeta Sorescu
Chair: Dr Constanta Popa
A certificate of participation was provided at the end of the webinar.
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
IFCC has been involved in the fight against the COVID-19 pandemic since it began. This has included producing webinars for the training and education of laboratory professionals. Laboratory specialists from around the world are involved in the fight against the COVID-19 pandemic. Some of the main challenges remaining include the limited testing capacity for SARS-CoV-2, the professional training of specialists, and maintaining quality control during diagnosis, standardization, prognostication, and therapeutic monitoring of patients with COVID-19.
During the webinar, the speakers discussed:
- "Increasing the testing capacity for SARS-CoV-2 molecular detection by specimen pooling: a practical guide for diagnostic centers" – Dr. Daniel Cruceriu
- "Specialist role in the analytical phase of laboratory diagnosis of SARS-CoV-2” – Dr. Mirela Ahmadi
- "Quality Management - EQC a useful tool for IQC" – Dr. Constanta Popa and Dr. Georgeta Sorescu
Chair: Dr Constanta Popa
A certificate of participation was provided at the end of the webinar.
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
The Corporate Townhall is a unique opportunity to bring everyone together in these regions and allow for exchange of ideas and free communication between various organizations.
September 21st, 2021
09.00 am-12:00 pm (Eastern Standard Time (EST) zone – New York)
IFCC Corporate members interested in participating in this open communication forum to significantly enhance communication within our laboratory medicine community had the possibility to attend and could ask question in the Discussion Forum via chat.
Format: brief presentations by IFCC EB together with Executive Boards of AFCB, AFCC, EFLM Regional Federations followed by a Discussion Forum.
gave brief presentations to update the membership on current and upcoming IFCC programmes and new initiatives globally and in specific regions.
Two other Townhalls are planned in October for the Americas (NAFCC and COLABIOCLI) as well as Asia-Pacific (APFCB), in their own time zones.
]]>
Dear Colleagues,
IFCC has been involved in the fight against the COVID-19 pandemic since it began. This has included producing webinars for training and education of laboratory professionals. Laboratory specialists from around the world are involved in the fight against the COVID-19 pandemic. Some of the main challenges remaining include the limited testing capacity for SARS-CoV-2, the professional training of specialists and maintaining quality control during diagnosis, standardisation, prognostication and therapeutic monitoring of patients with COVID-19.
We invite you to participate in this webinar, where the speakers will discuss the topic.
The Webinar will consist of three talks (20 minutes each) and will be followed by the panel discussion. Registrants will be able to ask questions to the presenters.
Chair: Dr Constanta Popa
- "Increasing the testing capacity for SARS-CoV-2 molecular detection by specimen pooling: a practical guide for diagnostic centers" – Dr. Daniel Cruceriu
- "Specialist role in analytical phase of laboratory diagnosis of SARS-CoV-2” – Dr. Mirela Ahmadi
- "Quality Management - EQC a useful tool for IQC" – Dr. Constanta Popa and Dr. Georgeta Sorescu
Certificate of participation will be provided at the end of this webinar. Please feel free to share this event in your social media with #IFCCLive Webinars.
Click here to convert your time zone
The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital
]]>
